Robert Way/iStock Editorial via Getty Images The Market Is Still Underestimating AMD’s Position Investors have spent many years viewing Advanced Micro Devices, Inc. ( AMD ) as a cyclical challenger as opposed to one of the most compelling companies in the world for the AI infrastructure era. That old way of viewing things is clearly no longer valid. AMD is now far more than just a CPU share-gain s...
Robert Way/iStock Editorial via Getty Images The Market Is Still Underestimating AMD’s Position Investors have spent many years viewing Advanced Micro Devices, Inc. ( AMD ) as a cyclical challenger as opposed to one of the most compelling companies in the world for the AI infrastructure era. That old way of viewing things is clearly no longer valid. AMD is now far more than just a CPU share-gain story. It has EPYC CPUs , Instinct accelerators, ROCm software, and the list goes on. This places the company much closer to the center of AI infrastructure spending than the market used to assume. The most critical point in the system is not only who has the fastest single chip, but who can help customers deploy enough compute at scale. This clearly shows why AMD’s opportunity is expanding. In its most recent reported quarter , AMD said Q4 2025 revenue rose 36% year over year to $10.2 billion, while full-year 2025 revenue rose 32% to $33.7 billion. Data Center revenue was a record $4.3 billion in Q4, up 22% year over year, while full-year Data Center revenue reached a record $14.3 billion, up 39%. AMD’s strategic pillars (AMD) AI Demand Is Moving Toward AMD’s Strengths The most important part of the bullish case is that AI demand is not static. The market largely still likes to frame AI chips as a one-company story. This is a far underestimation of how large the AI buildout is becoming, and how much customers want a serious contender to Nvidia ( NVDA ). AMD correctly described its AI roadmap as an open ecosystem strategy. The company revealed important plans like the Instinct MI350 series, continued ROCm development, and rack-scale designs. It also previewed Helios , a rack-scale reference design based on future MI400 GPUs, EPYC “Venice” CPUs, and Pensando networking. This is incredibly important as AI infrastructure is becoming more and more a full-stack systems problem rather than a single-chip purchasing decision. AMD Instinct MI350X accelerator (AMD Advancing AI 2025 Pr...
Robert Way/iStock Editorial via Getty Images The Market Is Still Underestimating AMD’s Position Investors have spent many years viewing Advanced Micro Devices, Inc. ( AMD ) as a cyclical challenger as opposed to one of the most compelling companies in the world for the AI infrastructure era. That old way of viewing things is clearly no longer valid. AMD is now far more than just a CPU share-gain s...
Robert Way/iStock Editorial via Getty Images The Market Is Still Underestimating AMD’s Position Investors have spent many years viewing Advanced Micro Devices, Inc. ( AMD ) as a cyclical challenger as opposed to one of the most compelling companies in the world for the AI infrastructure era. That old way of viewing things is clearly no longer valid. AMD is now far more than just a CPU share-gain story. It has EPYC CPUs , Instinct accelerators, ROCm software, and the list goes on. This places the company much closer to the center of AI infrastructure spending than the market used to assume. The most critical point in the system is not only who has the fastest single chip, but who can help customers deploy enough compute at scale. This clearly shows why AMD’s opportunity is expanding. In its most recent reported quarter , AMD said Q4 2025 revenue rose 36% year over year to $10.2 billion, while full-year 2025 revenue rose 32% to $33.7 billion. Data Center revenue was a record $4.3 billion in Q4, up 22% year over year, while full-year Data Center revenue reached a record $14.3 billion, up 39%. AMD’s strategic pillars (AMD) AI Demand Is Moving Toward AMD’s Strengths The most important part of the bullish case is that AI demand is not static. The market largely still likes to frame AI chips as a one-company story. This is a far underestimation of how large the AI buildout is becoming, and how much customers want a serious contender to Nvidia ( NVDA ). AMD correctly described its AI roadmap as an open ecosystem strategy. The company revealed important plans like the Instinct MI350 series, continued ROCm development, and rack-scale designs. It also previewed Helios , a rack-scale reference design based on future MI400 GPUs, EPYC “Venice” CPUs, and Pensando networking. This is incredibly important as AI infrastructure is becoming more and more a full-stack systems problem rather than a single-chip purchasing decision. AMD Instinct MI350X accelerator (AMD Advancing AI 2025 Pr...
格隆汇4月29日|零食制造商亿滋国际公布第一季度业绩,营收达100.8亿美元,同比增长逾8%,超过市场预期;纯利5.6亿美元,同比增长39.3%;经调整每股盈利67美仙,以固定汇率计跌14.9%,逊于市场预期的73美仙。公司董事长兼首席执行官Dirk Van de Put表示,首季业绩稳健,主要由新兴市场的强劲收入增长带动,已发展市场亦见改善迹象。展望方面,公司重申2026年全年指引,预期有机净收...
格隆汇4月29日|零食制造商亿滋国际公布第一季度业绩,营收达100.8亿美元,同比增长逾8%,超过市场预期;纯利5.6亿美元,同比增长39.3%;经调整每股盈利67美仙,以固定汇率计跌14.9%,逊于市场预期的73美仙。公司董事长兼首席执行官Dirk Van de Put表示,首季业绩稳健,主要由新兴市场的强劲收入增长带动,已发展市场亦见改善迹象。展望方面,公司重申2026年全年指引,预期有机净收入增长介乎持平至2%,按固定汇率计算的经调整每股盈利增长介乎持平至5%,并预期全年自由现金流约30亿美元。
Government request follows contingency planning to stop planes being grounded if Iran war supply shocks continue Business live – latest updates British refineries have been asked to maximise jet fuel supply as part of government contingency planning, amid growing fears the Iran war will force planes to be grounded. The energy minister Michael Shanks said the government is closely monitoring UK jet...
Government request follows contingency planning to stop planes being grounded if Iran war supply shocks continue Business live – latest updates British refineries have been asked to maximise jet fuel supply as part of government contingency planning, amid growing fears the Iran war will force planes to be grounded. The energy minister Michael Shanks said the government is closely monitoring UK jet fuel stocks and working with airlines, airports, fuel suppliers and other governments, as carriers face rocketing fuel costs as a result of the conflict. Continue reading...
SEATTLE, April 29, 2026--Veeam® Software, the Data and AI Trust Company, today announced the appointment of Rashmi Garde as Chief Legal Officer (CLO). Garde will lead Veeam’s global legal and compliance function, providing the foundation for trust as the company scales its operational pace and governance priorities in an AI-first world.
SEATTLE, April 29, 2026--Veeam® Software, the Data and AI Trust Company, today announced the appointment of Rashmi Garde as Chief Legal Officer (CLO). Garde will lead Veeam’s global legal and compliance function, providing the foundation for trust as the company scales its operational pace and governance priorities in an AI-first world.
Enterprise Products Partners (NYSE: EPD) had a record-breaking first quarter. The energy midstream company set several new operational records during the period, fueled by new expansion projects and war-driven export demand. That helped drive strong financial results in the period. Here's a look at the quarter and what the high-yielding (currently 5.7%) master limited partnership (MLP) sees ahead....
Enterprise Products Partners (NYSE: EPD) had a record-breaking first quarter. The energy midstream company set several new operational records during the period, fueled by new expansion projects and war-driven export demand. That helped drive strong financial results in the period. Here's a look at the quarter and what the high-yielding (currently 5.7%) master limited partnership (MLP) sees ahead. Image source: Getty Images. Continue reading
Vladislav Stepanov/iStock via Getty Images Kazia Therapeutics Limited ( KZIA ) is a clinical-stage oncology company that develops several programs. Their lead asset is Paxalisib, in Phase 2/3 in glioblastoma (GBM), with results in GBM showing meaningful concurrent-control survival data. Paxalisib is also studied in multiple central nervous system (CNS) related indications that are studied in Phase...
Vladislav Stepanov/iStock via Getty Images Kazia Therapeutics Limited ( KZIA ) is a clinical-stage oncology company that develops several programs. Their lead asset is Paxalisib, in Phase 2/3 in glioblastoma (GBM), with results in GBM showing meaningful concurrent-control survival data. Paxalisib is also studied in multiple central nervous system (CNS) related indications that are studied in Phase 2, such as diffuse intrinsic pontine glioma (DIPG), atypical teratoid/rhabdoid tumor (AT/RT), brain metastases, and central nervous system lymphoma. Paxalisib is a candidate for triple-negative breast cancer (TNBC). Other programs include EVT801 for advanced solid tumors, NDL2 as a PD-L1 protein degrader, and a new platform called SETDB1. Despite this diverse pipeline, I ultimately think KZIA lacks concrete near-term catalysts that could rerate the stock higher, which is why I’m neutral for now. Paxalisib: Overlooked Oncology Kazia Therapeutics Limited is a clinical-stage biotechnology company that develops drugs for the treatment of cancers of the central nervous system (CNS) and solid tumors. KZIA traces its roots to Novogen Limited, which was founded back in 1994. It later changed its strategy and its name to Kazia in 2016. The company is currently headquartered in Sydney, Australia. Interestingly, I noticed this small biotech has a relatively diverse oncology pipeline, yet it’s mostly undercovered despite targeting sizable TAMs for cancer treatments. The stock has also been performing well since its 2025 lows, so I thought it was worthwhile looking into this name. Source: Seeking Alpha Charts. As a quick overview, KZIA’s leading asset is Paxalisib, which Genentech , a member of the Roche Group ( RHHBY ), initially developed. Eventually, KZIA entered into a worldwide exclusive agreement with Genentech to develop and commercialize the drug. Under the agreement, Novogen/Kazia paid Genentech $5 million, with additional payments tied to milestones and royalties. Source: Cor...
iAnthus Capital Holdings ( ITHUF ) on Wednesday announced that Jason Ware has been appointed Chief Financial Officer, effective immediately. Immediately prior to the appointment of Ware as CFO, Justin Vu resigned as CFO of the company. Vu has served as the company’s CFO since January 6, 2025. Ware brings more than twenty years of finance leadership experience across public companies, including Gen...
iAnthus Capital Holdings ( ITHUF ) on Wednesday announced that Jason Ware has been appointed Chief Financial Officer, effective immediately. Immediately prior to the appointment of Ware as CFO, Justin Vu resigned as CFO of the company. Vu has served as the company’s CFO since January 6, 2025. Ware brings more than twenty years of finance leadership experience across public companies, including Genesco, Nutrafol, Victoria’s Secret, and L Brands. Press Release More on iAnthus Financial information for iAnthus
Nancy Pexton, 70, stabbed sister Jennifer Abbott, 69, and left her body to decompose in Camden flat for three days A woman has been found guilty of murdering her sister by slashing her neck before making off with her diamond-encrusted gold Rolex watch. Nancy Pexton stabbed her sibling Jennifer Abbott 10 times and then left her body for three days in her flat in Camden, north London, a court heard....
Nancy Pexton, 70, stabbed sister Jennifer Abbott, 69, and left her body to decompose in Camden flat for three days A woman has been found guilty of murdering her sister by slashing her neck before making off with her diamond-encrusted gold Rolex watch. Nancy Pexton stabbed her sibling Jennifer Abbott 10 times and then left her body for three days in her flat in Camden, north London, a court heard. Continue reading...